QuantuMDx included on PHE Microbiology Framework

8th June 2021 | QuantuMDx Team

  • Diagnostic Goods and Services (Lot 1)
  • Research and Development Goods (Lot 2)

NEWCASTLE UPON TYNE, UK, 08 June 2021. QuantuMDx has been successful in both Public Health England (‘PHE’) tenders the Company applied for. QuantuMDx will be included in the Framework Agreements under PHE’s National Microbiology Framework for Lot 1 (Diagnostic Goods and Services) and Lot 2 (Research and Development Goods).

Under Lot 1 of the Framework Agreement, QuantuMDx is now able to sell its SARS-CoV-2 RT-PCR Detection Assay for laboratories, as well as Q-POC™, its rapid, PCR point of care diagnostic system. Lot 2 will enable QuantuMDx to sell its Q-POC™ SARS-CoV-2 Assay, when the system is launched later this year.

Q-POC in operation

The term of the Framework Agreement for Lot 1 is for an initial two years with options to extend by up to a further two years. Lot 1 is a £3bn tender to be satisfied by multiple successful bidders. Similarly, Lot 2 is a £1.5bn framework to be satisfied over two years by multiple successful bidders.

Jonathan O’Halloran, Chief Executive, QuantuMDx, said: “I am very pleased that QuantuMDx has been successful in its tender to be included in both PHE Framework Agreements we applied for, validating the potential of our rapid point of care molecular diagnostic system, Q-POC™, and accompanying SARS-CoV-2 test. The COVID-19 crisis has highlighted the need for a robust testing infrastructure and this framework will support the UK’s testing strategy now and in the future.

“This award is testament to the high quality and hard work of the whole QuantuMDx team and we are equally proud to support the PHE, NHS and Department of Health and Social Care (‘DHSC‘) as the UK scales its testing capabilities to a  world leading level.”

The award of a framework contract is not exclusive to QuantuMDx, nor a guarantee of orders. It does, however, allow participating authorities to issue call-off orders for products and testing services in the future.


 About QuantuMDx:

QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com

For media enquiries:

Debra Daglish, Marketing Communications Manager, QuantuMDx Group

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, 0203 709 5700/ quantumdx@consilium-comms.com

For investor enquiries:

Financial Adviser: WG Partners LLP; David Wilson (020 3705 9315), Nigel Barnes (020 3705 9318), Claes Spång (020 3705 9317)

For more information:

Please email info@quantumdx.com